Delivery Order SPE2DB20D2001-SPE2DB26FPLKY
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, non-set-aside contract is valued at $1,807.80 and utilizes firm fixed price terms. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate office and primary distribution...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Jardiance 25 mg tablets (90-count) with a contract ceiling value of $31,642.05. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Jardiance 25 mg tablets (90-count packages) valued at $23,033.06. This firm fixed-price delivery order, with an ultimate completion date of October 23, 2025, was competitively awarded with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, leveraging the company's extensive pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,325.30 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed price contract. This competitively awarded, non-set-aside order was issued on September 23, 2025, with an ultimate completion date of September 24, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,313.76 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count packages) on September 15, 2025, with an ultimate completion date of September 16, 2025. This firm fixed-price delivery order, which carries no set-aside designation, was awarded competitively and represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The...
- The Defense Logistics Agency (DLA) awarded a $42,982.24 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of Jardiance 25 mg tablets (90-count units). The contract, which is a non-set-aside competitive award, will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 16, 2025. This delivery order represents a single transaction within AmerisourceBergen's broader...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,489.84 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed-price contract. This competitively awarded, non-set-aside delivery order was executed on September 11, 2025, with an ultimate completion date of September 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of...
- The Defense Logistics Agency awarded a delivery order valued at $17,796.50 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count packages) on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed-price contract valued at $4,976.53. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-set-aside competitive procurement. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Jardiance 25 mg tablets (90-count units) under a firm fixed-price contract type. The order, valued at $4,520.58, is scheduled for completion by July 21, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designations, reflecting AmerisourceBergen's established capability to...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB26FPLKYDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,327.82 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count units). The contract, issued on October 31, 2025, with an ultimate completion date of November 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. This award was issued competitively and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen supplies a comprehensive range of medications and medical commodities to support military and veteran healthcare systems. The Jardiance order fulfills federal pharmaceutical supply requirements, with the DLA planning to transition to next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts that will involve multiple regional awards across several contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.3k | 10/31/25 |